Related Experiment Video
Updated: May 31, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
The molecular basis of herpesviruses as oncolytic agents
Laura Menotti1, Gabriella Campadelli-Fiume, Patrizia Nanni
1Department of Experimental Pathology, University of Bologna, Bologna, Italy.
Abstract:
Herpes simplex viruses (HSVs) have entered clinical trials as oncolytic agents. The following properties make them good candidates. It is a mild pathogen; drugs (Aciclovir) are available to control viral infection; the large genome is amenable to genetic engineering, they can be rendered cancer-specific by deletion of genes, envelope glycoproteins allow the insertion of heterologous ligands to achieve modification of the natural tropism. Genetically modified HSVs have been thoroughly tested in humans. New generation recombinants retargeted to cancer-specific heterologous receptors have been generated and are presently evaluated in pre-clinical settings. They will be reviewed along with the molecular bases of cancer specificity and the strategies for the enhancement of oncolytic potential of HSV recombinants.
Related Concept Videos
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers
Antiviral Nucleoside Inhibitors
Herpes
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

